Using Patient Preference to Inform Ritlecitinib Dose Selection for Alopecia Areata Treatment

This study involved 201 adult patients from the US and EU to determine patient preferences for ritlecitinib dosing in alopecia areata treatment, focusing on the balance between hair regrowth benefits and safety risks. It found that the 50 mg dose of ritlecitinib led to greater hair regrowth (23%) compared to the 30 mg dose (14.3%), with patients willing to accept higher risks of serious infections, cancer, and blood clots for these benefits. US patients were less tolerant of blood clot and infection risks than EU patients, though cancer risk tolerance was similar. The study underscores the importance of considering patient preferences in treatment decisions to enhance patient-centric care and shared decision-making.